Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

141. Lung cancer and mesothelioma service guidance during the COVID-19 pandemic

When indicated, use PET-CT prior to any staging EBUS and to identify alternative biopsy target. o In cases where there is a low risk of mediastinal disease, consider percutaneous lung biopsy or proceeding directly to treatment based on lung cancer probability (including the use of the Herder model) ? Omit contrast enhanced CT brain in clinical stage II lung cancer. ? Do not perform full lung function testing when the clinician and surgeon are happy with simple spirometry. ? Do not perform (...) for SABR without nodal disease and tumours <2cm, consider SABR rather than surgery when surgical capacity is reduced. ? Consider delaying radiotherapy treatment until risk of exposure reduces in patients with stage I-II disease ? Use hypo-fractionated regimens wherever possible- See RCR emergency paper for protocols. ? Consider omitting induction component of chemoradiation and limiting to concurrent therapy. ? Consider temporarily stepping down routine post radical treatment surveillance

2020 British Thoracic Society

142. Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline Full Text available with Trip Pro

biomarker evaluation guideline. - TABLE 3 Recommendations on Symptom Management TABLE 4 Recommendations on Diagnosis TABLE 5 Recommendations on Staging Symptom Management Recommendations for assisting patients with symptoms of advanced colorectal cancer such as pain or bleeding are in . Discussion. More than 1.8 million patients in the world were diagnosed with colorectal cancer (CRC) in 2018. Among all patients with CRC, 20%-30% have metastatic disease from the outset (synchronous primary tumor (...) chemotherapy. , , , , In regions with fewer resource constraints, such as enhanced and maximal settings, doublet or triplet (FOLFOXIRI) chemotherapies should be available. NCCN, ESMO, and Cancer Council Australia guidelines advise that triplet chemotherapy (FOLFOXIRI) may be discussed for select patients, especially those appropriate for intensive chemotherapy, with large amount of disease burden, and when significant tumor shrinkage is the goal. , For patients treated with oxaliplatin-based chemotherapy

2020 American Society of Clinical Oncology Guidelines

143. ASTRO/ESTRO Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic Full Text available with Trip Pro

ASTRO/ESTRO Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement - ScienceDirect JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page. COVID-19 campus closures: to subscribed content Share Export Available online 6 April 2020 Practice recommendations for lung cancer radiotherapy during the COVID-19 (...) pandemic: An ESTRO-ASTRO consensus statement Author links open overlay panel … Show more Under a Creative Commons open access Highlights • Risk-mitigation pandemic scenario: efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. • Postponement or interruption of radiotherapy of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection

2020 American Society for Radiation Oncology

144. Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V

larotrectinib (N = 72) ? with NTRK gene fusion (n = 10) ? without NTRK gene fusion (n = 62) Subpopulations of patients with NTRK gene fusion analysed by the company: ? ePAS2 d (n = 8) ? salivary gland cancer (n = 3) ? gastrointestinal stromal cancer (n = 2) ? lung cancer - NSCLC (n = 1) ? soft tissue sarcoma (n = 1) ? thyroid cancer (n = 1) ? SAS3 e (n = 0) Data cut-off 19 February 2019: ? ESMO 2019 f (n = 12) ? separated by tumour histology: ND ? SAS3 e (n = 0) Screening: 4 weeks Treatment: until disease (...) Larotrectinib (solid tumours) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Larotrectinib (solide Tumore mit einer neurotrophen Tyrosin-Rezeptor-Kinase [NTRK]-Genfusion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 January 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

145. Relationship between volumes of services and quality of treatment outcome in the surgical treatment of breast cancer - rapid report

. In men, genetic factors and hormonal changes are the main factors responsible for the development of breast cancer [12-16]. Breast cancer precursors Breast cancer precursors are cell changes associated with an elevated risk of breast cancer. In addition to lesions of unclear biological potential, these precursors include ductal carcinoma in situ (DCIS), which develops within the milk ducts and has not yet grown into surrounding tissue. Due to the higher risk of it developing into malignant invasive (...) carcinoma when compared to other breast cancer precursors, surgical removal is always recommended for DCIS [13, 14, 17]. Tumour classification To describe the clinical and pathological spread of a carcinoma, it is classified on the basis of its size (T), lymph node involvement (N), and presence of distant metastases (M) (TNM classification) [14, 17, 18]. Other factors taken into account when classifying the tissue and assessing the chances for recovery include cancer tissue differentiation (grading

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

146. Joint statement from the Society for Endocrinology and the British Thyroid Association regarding ‘Association of Radioactive Iodine Treatment with cancer mortality in patients with hyperthyroidism’

. Nat Rev Endocrinol. 2016;12(6):313-314. 12. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignan- cies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-1644. 13. Yu CY, Saeed O, Goldberg AS, et al. A systematic review and me- ta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. Thyroid. 2018;28(12):1662-1673. 14. Hill AB. The environment and disease: association or causation? 1965. J R Soc Med. 2015;108(1):32-37. 15 (...) cancer patients (mean iodine-131 activity varied from 3700 to 5500 MBq). 13 A small risk of leukaemia was observed at these doses but there was no significant increase in the occurrence of breast cancer or other solid malignancies. 13 A causative role for radioiodine in the study by Kitahara et al thus seems unlikely given that excess risk was only observed for solid malignancies in their study, and the mean administered radioiodine activity (375 MBq for Graves' disease and 488 MBq for toxic nodules

2020 British Thyroid Association

147. Oxodotreotide (Netspot) - adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs)

Oxodotreotide (Netspot) - adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2020 Health Canada - Drug and Health Product Register

148. eUpdate – Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations

C et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018; 119: 1075–1085. Colombo N, Sessa C, du Bois A et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019; 30: 672–705. Oza AM (...) eUpdate – Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations Search eUpdate – Ovarian Cancer Treatment Recommendations eUpdate – Relapsed Epithelial Ovarian Carcinoma Treatment Recommendations Published: 01 April 2020 . Authors: ESMO Guidelines Committee Clinical Practice Guidelines This update refers to . Ledermann JA, Raja FA, Fotopoulou C et al. Ann Oncol 2013; 24 (Suppl 6): vi24–vi32. Section Chemotherapy

2020 European Society for Medical Oncology

149. Exercise in Cancer Care

that specific exercise programming adaptations may be required for people with cancer based on disease and treatment-related adverse effects, anticipated disease trajectory and their health status • Effective exercise prescriptions can be delivered across a variety of settings including hospital, cancer treatment centre, community and home-based (i.e. self-managed). • Accredited exercise physiologists or physiotherapists with experience in cancer care are the most appropriate health professionals (...) and functional ability), attenuating cancer- related fatigue, alleviating psychological distress and improving quality of life across multiple general health and cancer-specific domains [3-17]. Emerging evidence highlights that regular exercise before, during and/or following cancer treatment decreases the severity of other adverse side effects and is associated with reduced risk of developing new cancers and comorbid conditions such as cardiovascular disease, diabetes and osteoporosis [3, 4]. Furthermore

2020 Clinical Oncology Society of Australia

150. Early Breast Cancer

. For negative margins (i.e. ink not touching invasive cancer or DCIS), thedistanceofinvasivecancerand/orDCIS from the margin(s) should be reported. No tumour at the inked margin is required and>2mm for in situ disease is preferred [63–66]. Marking the tumour bed with clips in a standardised way facili- tates accurate planning of the radiation boost if indicated. Currently achievable low local recurrence rates [ 2mm for in situ disease is preferred [I, A]. Mastectomy: Besides simple mastectomy and skin (...) - rences and improved cosmetic outcomes [II, B]. Axillary node evaluation with SLNB is not required withinsitu malignancy but may be reasonable in large and/or high-grade tumours, especially when mastectomy is required (in case an inci- dental invasive cancer is subsequently identi?ed in the surgical specimen). The risk of a positive SLN with pure DCIS is small (7%–9%) and most of the metastases found are micrometastases or isolated tumour cells, detected by IHC [82, 83]. The decision to carry out

2020 European Society for Medical Oncology

151. eUpdate – Cervical Cancer Treatment Recommendations

or IB1 cervical cancer and a histological subtype of squamous-cell carcinoma, adenocarcinoma or adenosquamous carcinoma were randomly assigned to undergo minimally invasive surgery (laparoscopy or robot-assisted surgery) or conventional open surgery. Minimally invasive surgery was associated with a lower rate of disease-free survival (DFS) than open surgery [3-year rate, 91.2% versus 97.1%; hazard ratio (HR) for disease recurrence or death from cervical cancer 3.74; 95% confidence interval (CI) 1.63 (...) eUpdate – Cervical Cancer Treatment Recommendations eUpdate – Cervical Cancer Treatment Recommendations Search eUpdate – Cervical Cancer Treatment Recommendations eUpdate - Cervical Cancer Treatment Recommendations Published: 01 April 2020 . Authors: ESMO Guidelines Committee Clinical Practice Guidelines This update refers to . Section Management of local/locoregional disease; primary treatment Text update In the ESMO Clinical Practice Guidelines on cervical cancer, radical hysterectomy

2020 European Society for Medical Oncology

152. Darolutamide (Nubeqa) - prostate cancer

Darolutamide (Nubeqa) - prostate cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/58296/2020 EMEA/H/C/004790 Nubeqa (darolutamide) An overview of Nubeqa and why (...) it is authorised in the EU What is Nubeqa and what is it used for? Nubeqa is a medicine used to treat men with prostate cancer. It is used when the cancer is castration-resistant (worsens despite treatment to lower testosterone levels, including surgical removal of the testes) and is at high risk of metastasis (spreading to other parts of the body). Nubeqa contains the active substance darolutamide. How is Nubeqa used? Nubeqa is available as tablets (300 mg) and can only be obtained with a prescription

2020 European Medicines Agency - EPARs

153. CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

2020 Cardiovascular and Interventional Radiological Society of Europe

154. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules

EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lung cancer. It helps early detection of lung cancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lung cancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lung cancer recommends sputum cytology for investigation in people with suspected lung cancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided

2020 National Institute for Health and Clinical Excellence - Advice

155. Three-field versus two-field lymphadenectomy in transthoracic oesophagectomy for oesophageal squamous cell carcinoma: short-term outcomes of a randomized clinical trial

University Shanghai Cancer Centre, Shanghai, China. 7 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China. PMID: 32108326 DOI: Item in Clipboard Three-field Versus Two-Field Lymphadenectomy in Transthoracic Oesophagectomy for Oesophageal Squamous Cell Carcinoma: Short-Term Outcomes of a Randomized Clinical Trial B Li et al. Br J Surg . 2020 . Show details Br J Surg Actions . 2020 Feb 28. doi: 10.1002/bjs.11497. Online ahead of print. Authors (...) of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China. 7 Department of Thoracic Surgery, Henan Cancer Hospital, Zhengzhou, China. PMID: 32108326 DOI: Item in Clipboard Full-text links Cite Abstract in , Background: The benefit and harm of three-field lymphadenectomy for oesophageal cancer are still unknown. The aim of this study was to compare overall survival and morbidity and mortality between three- and two-field lymphadenectomy in patients with oesophageal squamous cell carcinoma

2020 EvidenceUpdates

156. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Full Text available with Trip Pro

Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S (...) Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Mar 11;annrheumdis-2019-216756. doi: 10.1136/annrheumdis-2019-216756. Online ahead of print. Risk of Breast Cancer Before and After Rheumatoid Arthritis, and the Impact of Hormonal Factors , , , Affiliations Expand Affiliations 1 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden hjalmar.wadstrom@ki.se. 2 Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet

2020 EvidenceUpdates

157. Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma

with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6: 469-476. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2018; 68: 55-63. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol 2008; 97: 221-225. Ahn D, Sohn JH, Jeon JH, Jeong JY. Clinical impact of microscopic (...) Recurrence following hemithyroidectomy in patients with low- and intermediate-risk papillary thyroid carcinoma Recurrence Following Hemithyroidectomy in Patients With Low- And Intermediate-Risk Papillary Thyroid Carcinoma - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National

2020 EvidenceUpdates

158. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)

trial conducted at the US Department of Veterans Affairs and National Cancer Institute sites. The participants were men (n=731) ≤75yr of age with localized prostate cancer, prostate-specific antigen (PSA) <50ng/ml, life expectancy ≥10yr, and medically fit for surgery. Intervention: Radical prostatectomy versus observation. Outcome measurements and statistical analysis: All-cause mortality was assessed in the entire cohort and patient and tumor subgroups. Intention-to-treat analysis was conducted (...) with intermediate-risk disease although not in men with high-risk disease. Patient summary: In this randomized study, we evaluated death from any cause in men with early prostate cancer treated with either surgery or observation. Overall, surgery may provide small very long-term reductions in death from any cause and increases in years of life gained. Absolute effects were much smaller in men with low-risk disease, but were greater in men with intermediate-risk disease although not in men with high-risk disease

2020 EvidenceUpdates

159. Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (the F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy

, Fuzhou, 350001, Fujian, People's Republic of China. chipan363@163.com. PMID: 32020327 DOI: Item in Clipboard Full-text links Cite Abstract Background: Coagulation and inflammation play important roles in tumor progression. This study aimed to explore the prognostic impact of combined analysis of fibrinogen and neutrophil-to-lymphocyte (NLR) ratio (F-NLR score) in locally advanced rectal cancer (LARC) receiving preoperative chemoradiotherapy (pCRT) and radical surgery. Method: Totally 317 patients (...) Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (the F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (The F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete

2020 EvidenceUpdates

160. Metformin plus megestrol acetate compared with MA alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial

Endometrial Cancer: A Randomised Controlled Trial , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Gynaecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. 2 Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai, China. 3 Department of Clinical Epidemiology, Obstetrics and Gynaecology Hospital, Fudan University, Shanghai, China. 4 Department of Cervical Diseases, Obstetrics and Gynaecology Hospital, Fudan University (...) for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012;207:266.e1-12. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803. Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, et al. Metformin

2020 EvidenceUpdates